Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA, USA.
Wiley Interdiscip Rev Syst Biol Med. 2012 Mar-Apr;4(2):207-20. doi: 10.1002/wsbm.164. Epub 2011 Oct 19.
The human body has limited regenerative capacity in most of the major tissues and organs. This fact has spurred the field of regenerative medicine, promising to repair damage following traumatic injury or disease. Multiple therapeutic strategies are being explored including small molecules, gene delivery, and stem cells; however, tissue engineering remains a primary approach to achieving regeneration. Organ transplantation demonstrates that damaged tissues can be replaced, but technology to regenerate complex organs de novo is not yet available. Instead, tissue engineering can augment the body's own regenerative ability by replacing tissue sections and enhancing the regenerative cascade. As a consequence of these opportunities, it is timely to review the criteria and current status of engineered tissue grafts designed as patches to replace or regenerate damaged or diseased tissue and restore organ function. This topic will be explored starting from the biomaterials and cells incorporated into the engineered graft, the environment into which the graft is implanted and the integration of the engineered graft with the host. Common issues will be addressed that are relevant to regeneration in multiple tissue and organ systems. Specific examples will focus on engineered grafts for myocardial and corneal repair to illustrate the tissue-specific challenges and opportunities and highlight the innovation needed as the field moves forward.
人体在大多数主要组织和器官中的再生能力有限。这一事实促使再生医学领域发展起来,有望在创伤性损伤或疾病后进行修复。目前正在探索多种治疗策略,包括小分子、基因传递和干细胞;然而,组织工程仍然是实现再生的主要方法。器官移植表明受损组织可以被替换,但尚未开发出从头再生复杂器官的技术。相反,组织工程可以通过替换组织部分和增强再生级联来增强身体自身的再生能力。由于这些机会,及时审查设计为贴片的工程化组织移植物的标准和现状,以替代或再生受损或患病组织并恢复器官功能是适时的。本主题将从纳入工程化移植物的生物材料和细胞、移植物植入的环境以及工程化移植物与宿主的整合开始进行探讨。将讨论与多个组织和器官系统再生相关的常见问题。具体示例将集中在用于心肌和角膜修复的工程化移植物上,以说明组织特异性的挑战和机遇,并强调随着该领域的发展所需的创新。